EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

doi:10.1093/annonc/mdz141

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2019

Hastings K, Yu H A, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon C A, Liu Z, Henick B S, Wurtz A, Cai G, Plodkowski A J, Long N M, Halpenny D F, Killam J, Oliva I, Schultz N, Riely G J, Arcila M E, Ladanyi M, Zelterman D, Herbst R S, Goldberg S B, Awad M M, Garon E B, Gettinger S, Hellmann M D, Politi K

Abstract excerpt

BACKGROUND: Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors responsive to immune checkpoint blockade. PATIENTS AND METHODS: We retrospectively analyzed de-identified clinical and molecular data on 171 cases of EGFR mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Drug Resistance, Neoplasm

Share to Genetic Heterogeneity

Share to Lung

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Share to Tobacco Smoking

Source

Open in PubMed Open full text

Identifiers

PMID: 31086949
DOI: 10.1093/annonc/mdz141
PMCID: PMC6683857

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.PMID 31086949Read ↗

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation SubtypesSemantic proximity Read ↗

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.Semantic proximity Read ↗

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Retrospective study on the clinicogenomic characteristics of <i>EGFR</i> mutant and wildtype NSCLCSemantic proximity Read ↗

EGFR mutant lung cancer.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.Semantic proximity Read ↗

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.